Vaccines in general and HIV vaccines in particular are focusing ever more on the induction
of cellular immunity specifically the generation of cytotoxic T cells (CTL). As progress is
made towards developing a safe and effective HIV vaccine, there is a need for a robust,
sensitive and reproducible assay to evaluate vaccine-induced cellular immunogenicity in
Phase II/III trials. The enzyme-linked immunospot (ELISPOT) assay fits these criteria and is a
technology that is readily transferable and amenable to high-through-put screening. There is …